Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Sympos ...

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The company will present findings on a novel GABAB receptor positive allosteric modulator for chronic cough at the Thirteenth London International Cough Symposium [1] Group 1: Company Overview - Addex Therapeutics is developing a portfolio of allosteric modulators targeting neurological disorders, with lead drug candidate ADX71149 having completed several Phase 2 clinical studies [3] - The second clinical program, dipraglurant, is under evaluation for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior for GABAB PAM programs, advancing multiple drug candidates for substance use disorder and an independent program for chronic cough [3] Group 2: GABAB Receptor and Chronic Cough - GABAB receptors are expressed in airways and the cough neural circuit, and their activation has been clinically validated with baclofen, a selective GABAB agonist [2] - Baclofen's use is limited due to side effects and loss of efficacy, while targeting an allosteric binding site of the GABAB receptor is expected to offer advantages like higher selectivity and better tolerability [2]

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The company will present findings on a novel GABAB receptor positive allosteric modulator for chronic cough at the Thirteenth London International Cough Symposium [1] - GABAB receptors are important in the cough neural circuit, and targeting them with allosteric modulators may offer advantages over traditional treatments like baclofen [2] Company Overview - Addex's lead drug candidate, ADX71149, is a positive allosteric modulator developed in collaboration with Janssen Pharmaceuticals and has completed several Phase 2 clinical studies [3] - The second clinical program, dipraglurant, is being evaluated for dyskinesia associated with Parkinson's disease and post-stroke recovery [3] - Addex is advancing a GABAB PAM program for chronic cough and has a partnership with Indivior for multiple drug candidates targeting substance use disorder [3] Research and Development - The upcoming presentation will focus on the antitussive activity of a novel GABAB receptor positive allosteric modulator in preclinical models [1] - GABAB receptor activation has been clinically validated with baclofen, but its use is limited due to side effects and tolerance issues [2] - Allosteric modulators are expected to provide higher selectivity and better tolerability compared to orthosteric compounds [2]

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM). The votes represented 33.79% of the company's outstanding capital. Addex shareholders approved the 2023 annual report, the 2023 annual ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q1 2024 Earnings Conference Call June 6, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Misha Kalinichev - Head, Translational Science Conference Call Participants Leonildo Delgado - Baader Helvea Operator Good day, and thank you for standing by. Welcome to the Addex Therapeutics First Quarter 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, the ...

Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements | Unaudited Interim Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 | 2 | | --- | --- | | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, | 3 | | 2023 and 2024 | | | Unaudited Interim Condensed Consolidated Statements of Changes in Equity f ...

● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2024 financial results and provided a corporate update. “Building on the recent Neurosterix transaction, which extende ...

● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2024 financial results and provided a corporate update. "Building on the recent Neurosterix transaction, which extended our cas ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1.   Approval of the Annual Report, the Annual Fi ...

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analys ...